The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 29 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Hypolipidemic Agents  [Clear All Filters]
2017
Lazaridis, N., & Tsochatzis E. (2017).  Current and future treatment options in non-alcoholic steatohepatitis (NASH).. Expert Rev Gastroenterol Hepatol. 11(4), 357-369.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Papademetriou, V., Lovato L., Tsioufis C., Cushman W., Applegate W. B., Mottle A., et al. (2017).  Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.. Am J Nephrol. 45(2), 136-145.
2016
Achimastos, A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., et al. (2016).  Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.. Hormones (Athens). 15(1), 8-14.
Tziomalos, K. (2016).  Unresolved issues in lipid-lowering treatment.. Panminerva Med. 58(2), 191-5.
2015
Tziomalos, K. (2015).  Clinical controversies in lipid management.. Panminerva Med. 57(2), 65-70.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.. Expert Rev Cardiovasc Ther. 13(9), 1059-66.
2014
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Achieving lipid targets in primary care settings.. Curr Med Res Opin. 30(10), 1971-4.
Tziomalos, K., Karagiannis A., & Athyros V. G. (2014).  Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.. Curr Pharm Des. 20(40), 6306-13.
Athyros, V. G., Katsiki N., & Rizzo M. (2014).  Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Curr Med Res Opin. 30(12), 2425-8.
2013
Kostapanos, M. S., Athyros V. G., Mikhailidis D. P., & Elisaf M. S. (2013).  Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.. J Clin Lipidol. 7(1), 88.
2012
Lazich, I., Sarafidis P., de Guzman E., Patel A., Oliva R., & Bakris G. (2012).  Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.. Diabetes Obes Metab. 14(2), 181-6.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Lipid lowering agents and the endothelium: an update after 4 years.. Curr Vasc Pharmacol. 10(1), 33-41.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Tsartsalis, A. N., Dokos C., Kaiafa G. D., Tsartsalis D. N., Kattamis A., Hatzitolios A. I., et al. (2012).  Statins, bone formation and osteoporosis: hope or hype?. Hormones (Athens). 11(2), 126-39.
2010
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Kirmizis, D., Papagianni A., Dogrammatzi F., Skoura L., Belechri A-M., Alexopoulos E., et al. (2010).  Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis.. J Atheroscler Thromb. 17(12), 1256-65.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.. Expert Opin Pharmacother. 11(5), 723-30.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Lipid-lowering agents and new onset diabetes mellitus.. Expert Opin Pharmacother. 11(12), 1965-70.
Chatzizisis, Y. S., Koskinas K. C., Misirli G., Vaklavas C., Hatzitolios A., & Giannoglou G. D. (2010).  Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.. Drug Saf. 33(3), 171-87.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
2009
Papademetriou, V., & Doumas M. (2009).  Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control.. Expert Opin Pharmacother. 10(6), 955-66.
2008
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Kakafika A. I., Karagiannis A., Koragiannis A., Mikhailidis D. P., & Mikhalidis D. P. (2008).  Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.. Am J Cardiol. 101(11), 1679-80.
2007
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2007).  Endothelial function, arterial stiffness and lipid lowering drugs.. Expert Opin Ther Targets. 11(9), 1143-60.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.